Company Profiles

driven by the PitchBook Platform

Lux Biosciences

Description

Developer of medications and drugs designed to treat ophthalmic diseases. The company's medications and drugs include LX201, silicone matrix ocular implant and Luveniq, an oral form of drug inhibitor voclosporin, enabling healthcare professionals to treat serious ophthalmic diseases.

2006

Founded

OOB

Status

11-50

Employees

Out of Business

Latest Deal Type

$152M

Total Amount Raised

7

Investors

Description

Developer of medications and drugs designed to treat ophthalmic diseases. The company's medications and drugs include LX201, silicone matrix ocular implant and Luveniq, an oral form of drug inhibitor voclosporin, enabling healthcare professionals to treat serious ophthalmic diseases.

Website:

www.luxbio.com

Ownership Status

Out of business

Financing Status

Formerly VC-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Harborside Financial Center Plaza 10 14th Floor Jersey City, NJ 07302United States +1 (201) 946-0551
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Lux Biosciences's full profile, request a free trial.

Lux Biosciences Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Lux Biosciences Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Lux Biosciences Investors (7)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Hatteras Venture PartnersVenture CapitalMinority000 0000000 0000
HBM Healthcare InvestmentsVenture CapitalMinority000 0000000 0000
HBM PartnersInvestment BankMinority000 0000000 0000
International Biotechnology TrustOtherMinority000 0000000 0000
NovoCorporate Venture CapitalMinority000 0000000 0000
Hatteras Venture Partners Venture Capital
HBM Healthcare Investments Venture Capital
HBM Partners Investment Bank
International Biotechnology Trust Other
Novo Corporate Venture Capital

Lux Biosciences Executive Team (2)

NameTitleBoard
Seat
Contact
Info
Dean MitchellPresident, Chief Executive Officer and Board Member
Eddy Anglade MDCo-Founder & Chief Medical Officer
Dean Mitchell President, Chief Executive Officer and Board Member
Eddy Anglade MD Co-Founder & Chief Medical Officer

Lux Biosciences Board Members (4)

NameRepresentingRoleSinceContact
Info
Axel BolteLux BiosciencesBoard Member000 0000
David Schnell MDProspect Venture PartnersCo-Founder, Partner & Managing Director000 0000
Paul ChaneyLux BiosciencesBoard Member000 0000
Thomas DyrbergLux BiosciencesBoard Member000 0000
Axel Bolte Board Member Lux Biosciences
David Schnell MD Co-Founder, Partner & Managing Director Prospect Venture Partners
Paul Chaney Board Member Lux Biosciences
Thomas Dyrberg Board Member Lux Biosciences
Request full access to PitchBook